Brain Scans to Learn How People With First-Episode Psychosis Respond to Risperidone or Aripiprazole
Uses brain scans in first-episode psychosis to study response to risperidone or aripiprazole.
Plain-language title generated from the registry record
Registry title: Cerebellum-based Imaging Neural Markers for Antipsychotic Response
Key facts
- Where
- Glen Oaks, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 40 years old?
Source: NCT07483294, who can take part
Where in United States
- Zucker Hillside HospitalGlen Oaks, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwell Health
- Trial code
- NCT07483294
- Record updated
- 26 May 2026
- Original description
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.Read full original descriptionShow less
Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.
Inclusion: Diagnosis of a first-episode psychotic disorder including: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychotic disorder Not Otherwise Specified (NOS), bipolar disorder with psychosis, and major depressive disorder with psychosis; Current positive symptoms rated > 3 (moderate) on one or more of the Brief Psychiatric Rating Scale (BPRS) psychosis items: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content; At early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 8 weeks or less; Age 15 to 40; Competent to sign informed consent.
Exclusion: Any medical condition which requires treatment with a medication with psychotropic effects; Serious neurological or endocrine disorder or brain trauma; Significant risk of suicidal or homicidal behavior; Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent; Contraindications to antipsychotic monotherapy; Contraindications to MR imaging (e.g. pacemaker); Pregnancy by self report.